Hcw Biologics INC. (HCWB) — 8-K Filings

All 8-K filings from Hcw Biologics INC.. Browse 39 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (39)

8-K Filing — Dec 31, 2025
HCW Biologics Files 8-K: Material Agreement & Equity Sales — Nov 20, 2025 Risk: medium
HCW Biologics Inc. announced on November 19, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity
HCW Biologics Enters Material Definitive Agreement — Nov 19, 2025 Risk: medium
HCW Biologics Inc. entered into a material definitive agreement on November 17, 2025. The filing does not disclose specific details of the agreement, such as th
8-K Filing — Nov 18, 2025
HCW Biologics Faces Delisting Notice — Oct 16, 2025 Risk: high
HCW Biologics Inc. filed an 8-K on October 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, effective Octob
HCW Biologics Enters Material Definitive Agreement — Sep 5, 2025 Risk: medium
HCW Biologics Inc. announced on September 2, 2025, that it entered into a material definitive agreement. The filing does not provide specific details about the
HCW Biologics Faces Delisting Concerns — Aug 19, 2025 Risk: high
HCW Biologics Inc. filed an 8-K on August 19, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company is i
HCW Biologics Files 8-K for Material Agreement — Aug 15, 2025 Risk: medium
HCW Biologics Inc. filed an 8-K on August 15, 2025, reporting an entry into a material definitive agreement on August 14, 2025. The filing also includes financi
HCW Biologics Files 8-K on Financials — Aug 14, 2025 Risk: low
HCW Biologics Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and
HCW Biologics Enters Material Definitive Agreement — Jul 18, 2025 Risk: medium
HCW Biologics Inc. announced on July 14, 2025, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreem
HCW Biologics Files 8-K for Other Event — Jul 1, 2025 Risk: medium
HCW Biologics Inc. filed an 8-K on June 18, 2025, reporting an 'Other Event'. The filing does not provide specific details about the event itself, only that it
HCW Biologics Files 8-K: Other Events & Financials — Jun 26, 2025 Risk: medium
HCW Biologics Inc. filed an 8-K on June 26, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details
HCW Biologics Files 8-K: Director/Officer Changes & Shareholder Votes — Jun 23, 2025 Risk: medium
HCW Biologics Inc. filed an 8-K on June 23, 2025, reporting events as of June 17, 2025. The filing covers the departure and election of directors, appointment o
HCW Biologics Files 8-K for Other Events — Jun 13, 2025 Risk: low
HCW Biologics Inc. filed an 8-K on June 13, 2025, reporting an event that occurred on June 12, 2025. The filing pertains to 'Other Events' and does not specify
HCW Biologics Files 8-K: Routine Update — Jun 5, 2025 Risk: low
HCW Biologics Inc. filed an 8-K on June 5, 2025, reporting other events and financial statements. The filing details the company's principal executive offices l
HCW Biologics Inc. Files 8-K with Material Agreement — Jun 4, 2025 Risk: medium
On May 29, 2025, HCW Biologics Inc. entered into a material definitive agreement. The company also reported on other events and filed financial statements and e
HCW Biologics Files 8-K for Other Events — May 30, 2025 Risk: medium
HCW Biologics Inc. filed an 8-K on May 30, 2025, reporting an event on May 28, 2025. The filing indicates 'Other Events' as the item information, with no specif
HCW Biologics Files 8-K: Other Events — May 23, 2025 Risk: medium
On May 21, 2025, HCW Biologics Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." No specific detail
HCW Biologics Files 8-K for Other Events — May 20, 2025 Risk: low
HCW Biologics Inc. filed an 8-K on May 20, 2025, reporting an event that occurred on May 15, 2025. The filing pertains to 'Other Events' and does not specify an
HCW Biologics Files 8-K Under 'Other Events' — Apr 22, 2025 Risk: medium
HCW Biologics Inc. filed an 8-K on April 22, 2025, reporting an event that occurred on April 17, 2025. The filing is categorized under 'Other Events' and does n
HCW Biologics Files 8-K: Material Agreement & Financials — Apr 14, 2025 Risk: medium
HCW Biologics Inc. filed an 8-K on April 14, 2025, reporting an entry into a material definitive agreement and other events. The filing also includes financial
HCW Biologics Files 8-K on Corporate Matters — Apr 1, 2025 Risk: low
HCW Biologics Inc. filed an 8-K on April 1, 2025, reporting on matters submitted to a vote of security holders and other events. The filing details the company'
HCW Biologics Enters Material Definitive Agreement — Mar 19, 2025 Risk: medium
HCW Biologics Inc. announced on March 17, 2025, that it entered into a material definitive agreement. The filing does not provide specific details about the agr
HCW Biologics Faces Delisting Concerns — Mar 6, 2025 Risk: high
HCW Biologics Inc. filed an 8-K on March 6, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing also includes finan
HCW Biologics Enters Material Definitive Agreement — Feb 21, 2025 Risk: medium
HCW Biologics Inc. announced on February 20, 2025, that it entered into a material definitive agreement. The filing does not disclose specific details of the ag
HCW Biologics Faces Delisting Concerns — Feb 7, 2025 Risk: high
HCW Biologics Inc. filed an 8-K on February 7, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company is also reportin
HCW Biologics Files 8-K — Feb 3, 2025 Risk: low
HCW Biologics Inc. filed an 8-K on February 3, 2025, to report information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing does
HCW Biologics Faces Delisting Concerns — Dec 23, 2024 Risk: high
HCW Biologics Inc. filed an 8-K on December 23, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of December
HCW Biologics Files 8-K: Material Agreement & Equity Sales — Nov 20, 2024 Risk: medium
HCW Biologics Inc. announced on November 18, 2024, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of equity
HCW Biologics Inc. Enters Material Definitive Agreement — Nov 18, 2024 Risk: medium
On November 18, 2024, HCW Biologics Inc. entered into a material definitive agreement and created a direct financial obligation. The specific details of this ag
HCW Biologics Changes Independent Auditor — Sep 20, 2024 Risk: medium
HCW Biologics Inc. announced on September 20, 2024, a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP and engaged With
HCW Biologics Faces Delisting Concerns — Aug 12, 2024 Risk: high
HCW Biologics Inc. filed an 8-K on August 12, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest eve
HCW Biologics Enters Material Definitive Agreement — Jul 18, 2024 Risk: medium
HCW Biologics Inc. announced on July 18, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreem
HCW Biologics Faces Delisting Notice — Jun 20, 2024 Risk: high
HCW Biologics Inc. filed an 8-K on June 20, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of June 17, 2024
HCW Biologics Files 8-K on Shareholder Votes — Jun 17, 2024 Risk: low
HCW Biologics Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders as of June 14, 2024. The filing details the compa
HCW Biologics Restates Financials — May 3, 2024 Risk: high
HCW Biologics Inc. announced on May 3, 2024, that it will not rely on previously issued financial statements. This decision impacts financial reporting and may
HCW Biologics Raises $2.4M in Direct Offering — May 1, 2024 Risk: medium
HCW Biologics Inc. announced on April 25, 2024, that it entered into a securities purchase agreement with an institutional investor for a registered direct offe
HCW Biologics Sells Unregistered Equity Securities — Feb 22, 2024 Risk: medium
HCW Biologics Inc. entered into a Material Definitive Agreement on February 20, 2024, involving the unregistered sale of equity securities. This 8-K filing, sub
HCW Biologics Terminates Material Definitive Agreement — Jan 12, 2024
HCW Biologics Inc. filed an 8-K on January 12, 2024, to report the termination of a material definitive agreement. This filing indicates a significant change in

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX